J. Beleta

发表

Synthesis and Evaluation of Some Pyrazolo[3,4-d]pyridazinones and Analogues as PDE 5 Inhibitors Potentially Useful as Peripheral Vasodilator Agents

V. D. Piaz, M. C. Castellana, C. Vergelli, 2002, Journal of enzyme inhibition and medicinal chemistry.

Studies on the cardiac actions of flosequinan in vitro

J. Beleta, R. Gristwood, P. Berga, 1992, British journal of pharmacology.

Pharmacological Assessment of the In Vitro Functional Selectivity of Aclidinium Bromide at M3 and M2 Muscarinic Receptors in Human Tissue

J. Cortijo, A. Gavaldá, J. Beleta, 2015, Pulmonary Therapy.

The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.

S. Sentellas, J. Montero, A. Gavaldá, 2014, Pulmonary pharmacology & therapeutics.

Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.

S. Sentellas, A. Gavaldá, J. Beleta, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Synthesis and structure-activity relationships of piperidinylpyrrolopyridine derivatives as potent and selective H1 antagonists.

J. Beleta, H. Ryder, Dolors Vilella, 2005, Bioorganic & medicinal chemistry letters.

Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor

J. Beleta, M. Miralpeix, M. Carmen Collado, 1998, British journal of pharmacology.

Phosphodiesterase 7A1 is expressed in human CD4+ naïve T cells at higher levels than in CD4+ memory cells and is not required during their CD3/CD28-dependent activation.

J. Beleta, N. Godessart, A. Nueda, 2006, Cellular immunology.

The In Vitro Pharmacological Profile Of LAS100977 - A Potent, Selective And Long-acting Beta-2 Receptor Agonist

J. Cortijo, A. Gavaldá, J. Beleta, 2010, ATS 2010.

A new chemical tool (C0036E08) supports the role of adenosine A(2B) receptors in mediating human mast cell activation.

M. Loza, J. Brea, M. Cadavid, 2008, Biochemical pharmacology.

Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.

J. Montero, A. Gavaldá, J. Beleta, 2011, European journal of medicinal chemistry.

Characterization of 5‐HT receptors on human pulmonary artery and vein: functional and binding studies

J. Palacios, J. Cortijo, J. Beleta, 1997, British journal of pharmacology.

Bronchodilator and anti‐inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes

J. Cortijo, J. Beleta, M. Martínez-Losa, 1999, British journal of pharmacology.

New pyrrolopyrimidin-6-yl benzenesulfonamides: potent A2B adenosine receptor antagonists.

M. Loza, M. Cadavid, J. Díaz, 2006, Bioorganic & medicinal chemistry letters.

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[

S. Sentellas, S. Espinosa, V. Segarra, 2009, Journal of medicinal chemistry.

Pharmacological Characterization of Abediterol, a Novel Inhaled β2-Adrenoceptor Agonist with Long Duration of Action and a Favorable Safety Profile in Preclinical Models

J. Cortijo, J. Beleta, H. Ryder, 2012, Journal of Pharmacology and Experimental Therapeutics.

Safety And Tolerability Of Twice-Daily Aclidinium Bromide In COPD Patients : ACCORD COPD

V. Peinado, J. Barberà, N. Prats, 2022 .

Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile.

J. Beleta, J. Gras, J. Aubets, 2012, Life sciences.

Functional Profile Of Aclidinium Bromide In Isolated Human Bronchi And Left Atria

J. Cortijo, J. Beleta, J. Milara, 2011, ATS 2011.

Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus

J. Cortijo, J. Beleta, R. Gristwood, 1993, British journal of pharmacology.

Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis.

J. Beleta, R. Gristwood, P. Berga, 1992, European journal of pharmacology.

Synthesis and structure-activity relationships of novel histamine H1 antagonists: indolylpiperidinyl benzoic acid derivatives.

J. Beleta, H. Ryder, J. Gras, 2004, Journal of medicinal chemistry.

Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.

M. Giovannoni, V. Segarra, J. Beleta, 1997, Journal of medicinal chemistry.

Heterocyclic-fused 3(2H)-pyridazinones as potent and selective PDE IV inhibitors: Further structure-activity relationships and molecular modelling studies

V. D. Piaz, M. Giovannoni, V. Segarra, 1998 .

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists.

S. Espinosa, V. Segarra, J. Beleta, 2011, Bioorganic & medicinal chemistry letters.

From Molecular Science to the Treatment of Allergy

M. Manns, Jane Wilkinson, P. Hufnagl, 1999, International Archives of Allergy and Immunology.

Adenosine inhibits macrophage colony-stimulating factor-dependent proliferation of macrophages through the induction of p27kip-1 expression.

J. Xaus, A. Valledor, A. Celada, 1999, Journal of immunology.

Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine.

J. Palacios, J. Beleta, J. Gras, 2000, European journal of pharmacology.

Pharmacological Profile of LAS 31180, a New Inotropic/Vasodilator Quinolone Derivative

J. Beleta, R. Gristwood, J. Gras, 2000, Arzneimittelforschung.

Inhibition of eotaxin‐mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram

J. Beleta, José Maria Palacios, L. Santamaria, 1997, British journal of pharmacology.

Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile

J. Cortijo, J. Beleta, H. Ryder, 2009, Journal of Pharmacology and Experimental Therapeutics.

Microsoft Word-71696817-file00

J. Cortijo, J. Beleta, H. Ryder, 2009 .

including studies withhumanbronchus

J. Cortijo, J. Beleta, R. Gristwood, 1993 .

Studies on thecardiac actions offlosequinan invitro

J. Beleta, R. Gristwood, P. Berga, 1992 .

Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist.

M. Loza, M. Cadavid, M. Calbet, 2007, Journal of medicinal chemistry.

In Vitro M3/M2 Kinetic Selectivity Of Aclidinium And Glycopyrrolate

J. Beleta, Dolors Vilella, M. Miralpeix, 2010, Asian Test Symposium.

In Vivo Studies Of Aclidinium And Glycopyrrolate To Assess Bronchodilatory Activity And Potential To Induce Dry Mouth

J. Beleta, M. Miralpeix, R. Otal, 2010, Asian Test Symposium.

Brain pyruvate oxidation in experimental thiamin-deficiency encephalopathy.

F. González-Sastre, J. Beleta, J. Beleta, 1996, Clinica chimica acta; international journal of clinical chemistry.

LAS100977, A Novel Beta-2 Receptor Agonist, With A Longer Duration Of Action And More Favourable Safety Margin Than Salmeterol In Anesthetised Dogs

J. Beleta, H. Ryder, J. Gras, 2010, ATS 2010.

A new chemical tool (C0036E08) supports the role of adenosine A(2B) receptors in mediating human mast cell activation.

M. Loza, J. Brea, M. Cadavid, 2008, Biochemical pharmacology.

Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile

J. Cortijo, J. Beleta, H. Ryder, 2009, Journal of Pharmacology and Experimental Therapeutics.

Purification and characterization of streptolysin O from Streptococcus pyogenes.

F. González-Sastre, J. Beleta, J. Beleta, 1992, The International journal of biochemistry.